Oncare Raises ₹27 Crore in Series A to Scale Affordable Cancer Care Across India.

Gurugram-based Cancer care startup Oncare has raised ₹27 crore (approximately $3 million) in a Series A funding round led by Sky Impact Capital, marking a significant milestone in India’s specialised oncology care segment. The round also saw participation from Huddle Ventures, Lotus Herbal Group, SteerX, and Tremis Capital.

Founded in 2023 by Amar Sneh and Deepak Kumar, Oncare operates cancer care units through a distributed model that partners with mid-sized, non-branded hospitals to offer oncology services. Instead of building stand-alone facilities, the startup integrates medical, surgical, and radiation oncology services within existing hospital infrastructure — a strategy that helps it accelerate expansion while keeping costs more affordable than those in large corporate centres.

Towards a Pan-India Oncology Network

The fresh capital will primarily be used to expand Oncare’s footprint beyond its current presence in the Delhi-NCR region into key metros like Bangalore, as well as tier-2 and tier-3 cities in Uttar Pradesh, Bihar, and West Bengal — regions where access to specialised cancer care remains limited.

Deepak Kumar, Co-Founder of Oncare, highlighted that the funding will accelerate the rollout of new centres and strengthen efforts to make standardised and transparent cancer care more accessible across India.

Addressing Pain Points in Cancer Treatment

Oncare’s model is rooted in addressing two of the biggest oncology healthcare challenges: affordability and transparency. According to the company, its integrated approach allows it to price chemotherapy sessions around 40% lower than at typical corporate hospitals — approximately ₹24,000–₹25,000 per session — and to offer surgeries at 30–40% lower costs.

In a market where treatment costs at large hospitals can soar well above ₹10 lakh for a complete course of treatment, Oncare’s cost-efficient model could significantly reduce financial barriers for patients seeking cancer care.

Since its inception, the startup reports it has interacted with close to 30,000 patients, conducted around 3,000 oncologist consultations, and facilitated over 1,000 treatment procedures — putting more than 4,000 care interactions on record.

Rising Investor Interest in Oncology

The funding for Oncare arrives amid a broader uptick in investment activity within India’s specialised healthcare segment. Across 2025 and early 2026, several cancer-focused startups have raised significant capital, including precision oncology platforms and AI-driven diagnostic ventures.

As cancer prevalence continues to rise and patients increasingly seek affordable, high-quality care, investors appear to be backing models that combine clinical excellence with scalable delivery.

Disclaimer

This article is based on publicly available media reports and industry sources and is intended for informational purposes only. Kalpway does not independently verify the accuracy or completeness of third-party information, and this content should not be construed as financial or investment advice.